Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results

Antonio González Martín • 29 Sep 2019
ESMO 2019
Gynecological Cancer Ovarian Cancer
PRIMA

Antonio González Martín, MD, Clínica Universidad de Navarra, Madrid, Spain, presents results from the Phase III PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016) of niraparib in newly diagnosed advanced ovarian cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals